公开(公告)号：US20230279090A1

公开(公告)日：2023-09-07

申请号：US18301187

申请日：2023-04-14

申请人： Genentech, Inc. ,  HOFFMANN-LA ROCHE INC.

发明人： Stefan Dengl ,  Rami Hannoush ,  Simon Theodor Hansen ,  Peter Michael Huelsmann ,  Robert Franklin Kelley ,  Hubert Kettenberger ,  Shrenik Chetan Mehta ,  Devin Brent Tesar

IPC分类号： C07K16/22 ,  C07K14/705 ,  A61P27/02

CPC分类号： C07K16/22 ,  A61P27/02 ,  C07K14/70578 ,  C07K14/70585

摘要： A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican.

公开(公告)号：US20230265177A1

公开(公告)日：2023-08-24

申请号：US18091056

申请日：2022-12-29

申请人： Hoffmann-La Roche Inc.

发明人： Stefan Dengl ,  Thomas Emrich ,  Guy Georges ,  Ulrich Goepfert ,  Fiona Grueninger ,  Adrian Hugenmatter ,  Anton Jochner ,  Hubert Kettenberger ,  Joerg Moelleken ,  Ekkehard Moessner ,  Olaf Mundigl ,  Jens Niewoehner ,  Tilman Schlothauer ,  Michael Molhoj ,  Kevin Brady

IPC分类号： C07K16/18

CPC分类号： C07K16/18 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/92 ,  A61K2039/505

摘要： The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

公开(公告)号：US11668722B2

公开(公告)日：2023-06-06

申请号：US16657753

申请日：2019-10-18

申请人： Hoffmann-La Roche Inc.

发明人： Hubert Kettenberger ,  Wolfgang Richter ,  Laurent Lariviere ,  Thomas Kraft ,  Thomas Emrich

IPC分类号： G01N33/68 ,  C07K16/18 ,  C07K16/28

CPC分类号： G01N33/686 ,  C07K16/18 ,  C07K16/2863

摘要： Herein is reported a method for selecting an antibody with a systematic clearance in cynomolgus monkeys of less than 8 mL/kg/day comprising the steps of measuring the retention time of the antibody on performing an FcRn affinity chromatography with a positive linear pH gradient and on a heparin affinity chromatography with a positive linear conductivity/salt gradient, and selecting an antibody that has a relative retention time on the FcRn affinity chromatography column is less than 1.78 times the retention time difference between peaks 2 and 3 the retention time of preparation of an oxidized anti-Her3 antibody of SEQ ID NO: 03 and 04, and a relative retention time on the heparin affinity chromatography column is less than 0.87 times the retention time of an anti-pTau antibody of SEQ ID NO: 01 and 02.

公开(公告)号：US10793621B2

公开(公告)日：2020-10-06

申请号：US15961699

申请日：2018-04-24

申请人： Hoffmann-La Roche Inc.

发明人： Birgit Bossenmaier ,  Hubert Kettenberger ,  Christian Klein ,  Klaus-Peter Kuenkele ,  Joerg-Thomas Regula ,  Wolfgang Schaefer ,  Manfred Schwaiger ,  Claudio Sustmann

IPC分类号： C07K16/30 ,  C12N15/13 ,  C12N5/10 ,  C07K16/00 ,  C07K16/28 ,  C07K16/32 ,  C12N15/85

摘要： The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.

公开(公告)号：US10465000B2

公开(公告)日：2019-11-05

申请号：US15389286

申请日：2016-12-22

申请人： Hoffmann-La Roche Inc.

发明人： Fiona Grueninger ,  Guy Georges ,  Olaf Mundigl ,  Michael Schraeml ,  Bernd Bohrmann ,  Ulrich Goepfert ,  Joerg Benz ,  Hubert Kettenberger

IPC分类号： A61K39/00 ,  C07K14/47 ,  C07K16/18 ,  A61K39/395

摘要： The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

公开(公告)号：US10418126B2

公开(公告)日：2019-09-17

申请号：US15061130

申请日：2016-03-04

申请人： Hoffmann-La Roche Inc.

发明人： Hubert Kettenberger ,  Stefan Klostermann ,  Florian Lipsmeier ,  Apollon Papadimitriou ,  Jasmin Sydow-Andersen

IPC分类号： G16B15/00 ,  G01N33/68 ,  C07K16/10 ,  C07K16/22 ,  G16C99/00

摘要： Herein is reported a method for selecting or deselecting an antibody comprising a) determining for each Asp and Asn residue in an antibody Fv region the conformational flexibility of the Cα-atom using a homology model ensemble, b) determining for each Asp and Asn residue in an antibody Fv region the size of the amino acid residue C-terminal to the Asp or Asn residue, and c) selecting an antibody in which the Cα-atom is conformationally inflexible and/or the Asp or Asn has a big C-terminal amino acid residue, or deselecting an antibody in which the Cα-atom has a moderate to high conformational flexibility and/or the Asp or Asn has a small C-terminal amino acid residue.

公开(公告)号：US20170227547A1

公开(公告)日：2017-08-10

申请号：US15271091

申请日：2016-09-20

申请人： Hoffmann-La Roche Inc.

发明人： Thomas Emrich ,  Hubert Kettenberger ,  Tilman Schlothauer ,  Angela Schoch

IPC分类号： G01N33/68 ,  B01D15/38 ,  B01D15/16

CPC分类号： G01N33/6854 ,  B01D15/168 ,  B01D15/3809 ,  C07K16/00 ,  C07K2317/52 ,  C07K2317/94

摘要： Herein is reported a method for determining the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life comprising the steps of a) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a first sodium chloride concentration, and b) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a second sodium chloride concentration, whereby the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life is determined if the retention time determined in step a) and the retention time determined in step b) are substantially different.

公开(公告)号：US12103967B2

公开(公告)日：2024-10-01

申请号：US18509252

申请日：2023-11-14

申请人： Hoffmann-La Roche Inc.

发明人： Jens Fischer ,  Guy Georges ,  Anton Jochner ,  Gregor Jordan ,  Hubert Kettenberger ,  Joerg Moelleken ,  Tilman Schlothauer ,  Georg Tiefenthaler ,  Valeria Runza ,  Meher Majety ,  Martin Schaefer ,  Maria Viert ,  Shu Feng ,  Wei Shiong Adrian Ho ,  Siok Wan Gan ,  Runyi Adeline Lam ,  Michael Gertz

IPC分类号： C07K16/46 ,  A61K39/385 ,  C07K16/24 ,  C12N5/00 ,  C12N15/09 ,  A61K39/00 ,  C12N5/07 ,  C12N15/63

CPC分类号： C07K16/24 ,  A61K39/385 ,  A61K2039/505 ,  C07K16/46 ,  C07K2317/31 ,  C07K2317/565 ,  C12N5/06 ,  C12N15/09 ,  C12N15/63

摘要： The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

公开(公告)号：US11572404B2

公开(公告)日：2023-02-07

申请号：US17023963

申请日：2020-09-17

申请人： Hoffmann-La Roche Inc.

发明人： Stefan Dengl ,  Thomas Emrich ,  Guy Georges ,  Ulrich Goepfert ,  Fiona Grueninger ,  Adrian Hugenmatter ,  Anton Jochner ,  Hubert Kettenberger ,  Joerg Moelleken ,  Ekkehard Moessner ,  Olaf Mundigl ,  Jens Niewoehner ,  Tilman Schlothauer ,  Michael Molhoj ,  Kevin Brady

IPC分类号： C07K16/18 ,  C07K14/47 ,  A61K39/395 ,  A61K39/00

摘要： The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

公开(公告)号：US20210199666A1

公开(公告)日：2021-07-01

申请号：US16998990

申请日：2020-08-20

申请人： Hoffmann-La Roche Inc.

发明人： Apollon Papadimitriou ,  Joerg Thomas Regula ,  Hubert Kettenberger ,  Joerg Moelleken ,  Christian Gassner

IPC分类号： G01N33/68 ,  G01N33/543 ,  G01N21/65

摘要： Herein is reported the use of a binding assay of a bivalent, bispecific antibody that has the smaller kD value (dissociation constant) for the interaction with its antigen for the immobilization of the bivalent, bispecific antibody to a solid surface for the determination of the biological activity of the bivalent, bispecific antibody.